Ipca Laboratories Financial Statements

Ipca Laboratories (IPCALAB) reported revenue of ₹89.40B in FY2025 with net income of ₹7.85B. Total assets stood at ₹117.61B. Net worth was ₹69.48B (₹6,948 Cr) and free cash flow was ₹5.46B.

Ipca Laboratories Income Statement

Hover the chart icon for year-over-year change.

FY 2024 – FY 2025

Item	Chart	2024	2025
Revenue		77.05B	89.40B
Cost of Rev. Cost of Revenue		-25.76B	-27.79B
Gross Profit		51.29B	61.61B
SGA Sales, General & Admin		-38.08B	-44.35B
Op. Income Operating Income		9.64B	13.28B
PBT Profit Before Tax		8.43B	11.31B
Net Income		5.23B	7.85B
Dil. Shares Diluted Shares		253.70M	253.67M
Diluted EPS		21.57	29.08

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Ipca Laboratories's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Ipca Laboratories Balance Sheet

Hover the chart icon for year-over-year change.

FY 2024 – FY 2025

Item	Chart	2024	2025
Curr. assets Total current assets		55.39B	62.69B
Non-curr. assets Total non-current assets		55.62B	54.92B
Total assets		111.01B	117.61B
Curr. liabilities Total current liabilities		23.56B	23.86B
Non-curr. liab. Total non-current liabilities		10.19B	9.86B
Total liabilities		33.74B	33.72B
Total equity		77.27B	83.88B
Total liab. & eq. Total liabilities & equity		111.01B	117.61B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Ipca Laboratories's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Ipca Laboratories Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2024 – FY 2025

Item	Chart	2024	2025
Net Income		8.43B	11.31B
Operating CF Cash flow Operating Activities		9.45B	13.21B
Capex Investments in PPE		-4.11B	-7.76B
Investing CF Cash flow Investing Activities		-12.92B	-8.70B
Dividend Paid		-507.40M	-1.01B
Financing CF Cash flow Financing Activities		-5.53B	-2.83B
Cash (start) Cash at beginning of period		15.79B	7.56B
Cash (end) Cash at end of period		7.56B	9.25B
FCF Free Cash Flow		5.34B	5.46B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Ipca Laboratories's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025